Physician

Glen Gejerman, MD

According to 2025 Medicare claims, Glen Gejerman, MD (NPI: 1972565182) practices radiation oncology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Bergen, NJ. This provider's primary affiliated billing organization is SUMMIT MEDICAL GROUP PA (NPI: 1942254347; TIN: 223487984) and primary practice location at 08003-2024. Gejerman is affiliated with the Summit Health ACO (ACO ID: A5049), participating under the MSSP model.

Gejerman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 857 traditional Medicare patients, billed 33,430 HCPCS/CPT codes, and received $6,331,128 in Medicare payments. The top billing code was G6015 (Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session). Part D data shows 761 prescription claims across 450 beneficiaries totaling $8,592 in drug costs, led by Tamsulosin Hcl (Tamsulosin Hcl). Open Payments data shows 28 records totaling $55,534. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,502,073 to $6,331,128. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $11,698 and ending at $8,592. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	662	11,300	$2,502,073
2016	763	24,701	$3,473,500
2017	1,164	33,535	$4,680,814
2018	752	20,423	$4,206,888
2019	699	20,348	$4,035,782
2020	596	21,986	$3,903,254
2021	842	30,415	$5,614,503
2022	829	27,578	$5,139,828
2023	836	36,848	$6,509,399
2024	857	33,430	$6,331,128

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	83	212	$11,698
2016	81	222	$11,240
2017	71	164	$7,105
2018	91	219	$8,881
2019	93	200	$5,455
2020	108	231	$14,044
2021	133	267	$25,232
2022	309	507	$8,042
2023	331	613	$8,529
2024	450	761	$8,592

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G6015	Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session	368	3,556	$312
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	360	360	$179
77427	Radiation treatment management, 5 treatment sessions	261	918	$157
77014	Ct guidance for insertion of radiation therapy fields	364	3,492	$103
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	280	313	$71

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tamsulosin Hcl	Tamsulosin Hcl	324	15,377	$4,953
Alendronate Sodium	Alendronate Sodium	62	5,242	$657
Ciprofloxacin Hcl	Ciprofloxacin Hcl	309	1,030	$530
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	33	$8

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	22	$37,854	Teleflex LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	6	$17,681	Boston Scientific Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Glen Gejerman, MD?

Tedicare shows public-source Medicare data for Glen Gejerman, MD (NPI 1972565182), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Glen Gejerman, MD have ACO affiliation data?

Glen Gejerman, MD is shown with ACO affiliation data for Summit Health ACO (MSSP, ACO ID A5049).

What billing organization is linked to Glen Gejerman, MD?

Glen Gejerman, MD is linked to SUMMIT MEDICAL GROUP PA (billing NPI 1942254347) in the available physician profile data.

Does Glen Gejerman, MD have Open Payments data?

Glen Gejerman, MD has 28 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.